1. Scrip

Major Milestone For Diurnal As FDA Approves Alkindi

Partner Eton Predicts $100m Sales For Adrenal Insufficiency Drug

 
• By Kevin Grogan

The US green light for Alkindi is a big step for the UK biotech in its bid to become a world-leading specialty endocrinology business.

Independence day
Diurnal celebrating after US approval of Alkindi • Source: Shutterstock

Diurnal Group PLC is confident that the successful launch of Alkindi in Europe will be repeated across the Atlantic now that the UK biotech's replacement therapy for adrenal insufficiency in infants has been approved in the US, with partner Eton Pharmaceuticals, Inc. ready to hit the ground running.

The US Food and Drug Administration has given the green light to Diurnal's oral treatment, which will be marketed as Alkindi Sprinkles (immediate-release hydrocortisone), making the only licensed treatment specifically designed for use in children with adrenal insufficiency in the US

More from New Products

More from Scrip

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.